Balsalazide

Balsalazide

Systematic (IUPAC) name
(E)-5-([4-(2-carboxyethylcarbamoyl)phenyl]diazenyl)-2-hydroxybenzoic acid
Clinical data
Trade names	Colazal
AHFS/Drugs.com	monograph
MedlinePlus	a699052
Pregnancy cat.	B(US)
Legal status	POM (UK)
Pharmacokinetic data
Bioavailability	<1%
Protein binding	≥99%
Half-life	12hr
Identifiers
CAS number	80573-04-2 Y
ATC code	A07EC04
PubChem	CID 5362070
DrugBank	APRD00141
ChemSpider	10662422 Y
UNII	P80AL8J7ZP Y
ChEBI	CHEBI:267413 Y
ChEMBL	CHEMBL102265 N
Chemical data
Formula	C17H15N3O6
Mol. mass	357.318 g/mol
SMILES	eMolecules & PubChem
InChI InChI=1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26)/b20-19+ Y Key:IPOKCKJONYRRHP-FMQUCBEESA-N Y
N(what is this?)  (verify)

Balsalazide is an anti-inflammatory drug used in the treatment of inflammatory bowel disease. It is sold under the name "Colazal" in the US and "Colazide" in the UK. It is also sold in generic form in the US by several generic manufacturers.

It is usually administered as the disodium salt.

Balsalazide releases mesalazine, also known as 5-aminosalicylic acid, or 5-ASA,^[1] in the large intestine. Its advantage over that drug in the treatment of ulcerative colitis is believed to be the delivery of the active agent past the small intestine to the large intestine, the active site of ulcerative colitis.

References

1. ^ Kruis, W.; Schreiber, I.; Theuer; Brandes; Schütz; Howaldt; Krakamp; Hämling et al. (2001). "Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses". Gut 49 (6): 783–789. doi:10.1136/gut.49.6.783. PMC 1728533. PMID 11709512. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1728533.  edit